Recce Pharmaceuticals (ASX:RCE) obtained Patent Family 3 in Australia for its R327 and R529 anti-infectives, effective until 2037, according to a Tuesday filing with the Australian bourse.
The pharmaceutical company said it is now patent-protected in all major pharmaceutical markets globally.